Mr. Bill Jackson reports

VECTOR SCIENCE & THERAPEUTICS ANNOUNCES DISTRIBUTOR NETWORK BUILDOUT TO SUPPORT ITS PEPTIDE PORTFOLIO ACROSS ORTHOPEDIC, SPORTS, AND REGENERATIVE MEDICINE CHANNELS

Vector Science and Therapeutics Corp. plans to build a dedicated distributor network to support commercialization of its peptide portfolio across the orthopedic, sports and regenerative medicine channels. The portfolio is focused on the clinical areas of musculoskeletal conditions, soft tissue injury and degenerative joint disease, including osteoarthritis. The specialized force is designed to place the company's peptide-based recovery offerings into the clinical settings where these conditions are managed.

The distributor force will concentrate on high-value call points across the orthopedic, sports and regenerative medicine ecosystem, including orthopedic and sports medicine practices, ambulatory surgery centres, regenerative medicine clinics, athletic training environments, and pain management and rehabilitation (PMR) settings. Vector will recruit experienced independent distributors and representatives with established relationships in these channels, enabling national coverage without the cost of building an in-house sales force.

The company intends to build a national distribution channel over time and may elect to concentrate its initial launch efforts regionally and/or by clinical specialty. This phased approach is intended to test the commercial model in select markets before scaling nationally.

Over time, the company anticipates this distributor force could grow into a national organization of up to approximately 20 distributors and as many as 300 subrepresentatives. The ultimate size of the force and the timeline for reaching it remain uncertain and are expected to scale with the pace of Vector's commercial sales growth.

"The distributors who serve these channels are among the most sophisticated in medtech," said Bill Jackson, chief executive officer of Vector Science. "Building a specialized force now ensures our portfolio reaches the market with the credibility clinicians expect."

"This force will put our peptide portfolio directly in front of the clinicians who treat these patients, through distributors who already have their trust," said Barry Hix, co-founder and chief commercial officer of Vector.

Strategic rationale

The distributor network initiative reflects three core commercial principles:

• Channel specialization: Orthopedic, sports and regenerative medicine call points require deep clinical fluency and established practitioner trust. A specialized distributor force delivers both from day one.
• Capital efficiency: An independent distributor model ties commercial costs to actual sales, preserving capital for clinical and regulatory work.
• Portfolio focus: Channel infrastructure dedicated to this portfolio lets Vector move quickly as individual products clear regulatory and market milestones.

The company expects to announce distributor partnerships and regional coverage milestones in the coming quarters.

About Vector Science and Therapeutics Corp.

Vector Science is a medical technology and therapeutic delivery company developing technologies intended to improve how pharmaceutical agents, peptides, biologics and other therapeutic compounds are delivered to target tissues.

The company's intellectual property portfolio spans advanced transdermal delivery, precision catheter systems, localized pain management, regenerative medicine, pancreatic oncology, smart wound care, lyophilized pharmaceutical systems and next-generation therapeutic delivery technologies.

Vector Science is headquartered in Mequon, Wis.

We seek Safe Harbor.